Bracco, ACIST Medical Systems Launch Acist Pro Diagnostic System in Europe

February 12, 2026—ACIST Medical Systems, a Bracco Group company, announced the launch of its Acist Pro diagnostic system in selected European markets after receiving CE Mark under the European Medical Device Regulation.

The Acist Pro next-generation, variable-rate contrast management system is designed to advance precision, safety, and efficiency in image-guided cardiovascular procedures, advised the company.

According to the company, Acist Pro represents an evolution of the company’s Acist CVi automated contrast delivery technology, which replaced manual injection in the cardiac catheterization laboratory with automated, real-time precision delivery. In clinical use, the Acist CVi system has demonstrated an average 45 mL reduction in contrast use, a 30% reduction in contrast-induced acute kidney injury, and an average of 5 minutes saved per case.

“The launch of Acist Pro is an important step in our ongoing effort to advance precision imaging across specialties,” said Dr. Fulvio Renoldi Bracco, CEO of Bracco Imaging, in the press release. “By thoughtfully evolving a trusted platform, we are responding to the real-world needs of today’s interventional teams. This milestone reflects our commitment to delivering practical, forward-looking solutions that support quality, safety, and sustainability in diagnostic imaging.”

“Building on the trusted Acist CVi system, Acist Pro is our next-generation solution, enhancing precision and efficiency in the cardiac catheterization laboratory. With its European launch, we are proud to bring this advanced technology to clinicians and continue our commitment to innovation in interventional imaging,” said Brad Fox, CEO of ACIST Medical Systems.

The company advised that FDA 510(k) clearance for Acist Pro is pending in the United States, with broader global availability anticipated throughout 2026. The system was first introduced in Japan in 2025.